Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study-Reference-Cited by-同舟云学术

Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study

Published:2014-04-07 Issue:6 Volume:24 Page:885-891
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Iwahashi Mitsuhiro,Inoue Hiroshi,Matsubara Tsukasa,Tanaka Takaaki,Amano Koichi,Kanamono Toshihisa,Nakano Teruaki,Uchimura Shoichi,Izumihara Tomomaro,Yamazaki Akira,Karyekar Chetan S.,Takeuchi Tsutomu

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

http://www.tandfonline.com/doi/pdf/10.3109/14397595.2014.881954

Reference27 articles.

1. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

2. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes

3. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial

4. Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study

5. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort;Reumatismo;2024-06-24

2. Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine;BioDrugs;2022-10-31

3. Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider;RMD Open;2022-06

4. Differences in patients’ population and efficacy/effectiveness of biologic disease–modifying antirheumatic drugs between randomized controlled trials and real-world settings in patients with rheumatoid arthritis – using the IORRA cohort;Modern Rheumatology;2021-09-10

5. Model‐Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis;The Journal of Clinical Pharmacology;2021-01-18